Curtis J. Henrich
Molecular Targets Laboratory, CCR
National Cancer Institute
United States of America
Curtis J. Henrich did Ph.D. in biochemistry from the University of Michigan (thesis research on erythrocyte senescence-related glycoconjugates). Post-doctoral research in Michigan and at the University of California, San Francisco was followed by 14 years in the biotechnology industry (Life Technologies, Inc. and a now defunct start-up called Aptus Pharmaceuticals). Joined the Molecular Targets Laboratory in 2003 first as a consultant, then as a Senior Scientist affiliated with Leidos Biomedical Research, Inc. (formerly SAIC-Frederick, Inc.) Dr. Henrich coordinates bioassay development, high-throughput screening, and application of assays to natural products isolation within the Molecular Targets Laboratory.
1) Bioassay development, 2) High-throughput screening, 3) Natural products isolation
High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells.
Compounds from Simarouba berteroana which inhibit proliferation of NF1-defective cancer cells.
Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor.